Dingell generic drug probe

Executive Summary

House Commerce/Oversight & Investigations Subcommittee plans to interview more than the 60 FDA employees it had initially targeted for questioning in its investigation into the agency's generic drug approval process. The subcommittee, chaired by Rep. Dingell (D-Mich.), expects to finish first round of interviews, including the 60 FDAers, during the week ending April 8. Dingell has said that the interviews are necessary due to the expansion of the generic drug approval inquiry launched last summer ("The Pink Sheet" March 20, p. 3).